BioPharm X Corp., a specialty pharmaceutical company focused on the dermatology market, recently shared early clinical and pre-clinical data for BPX-01 topical gel at the 2017 American Academy of Dermatology (AAD) Annual Meeting. Read More »
Immune Pharmaceuticals Inc. will broaden enrollment eligibility criteria for its 10-patient open label study of Bertilimumab in the treatment of Bullous Pemphigoid (BP) after data was compiled from three patients who completed treatment. Read More »
Incyte Corp. will conduct a multi-year research project in conjunction with the Abramson Cancer Center at the University of Pennsylvania aimed at advancing the understanding of cancer biology. Read More »
Teva Pharmaceutical Industries Ltd. has launched generic Pristiq 1 (desvenlafaxine) extended-release tablets in 25, 50 and 100 mg in the United States. Read More »
U.S. Congressmen Doug Collins (R-GA) and Dave Loebsack (D-IA) last week introduced a bill -- H.R. 1316, the Prescription Drug Price Transparency Act -- that they say would "require greater transparency from pharmacy benefit managers (PBMs)." In introducing the bill, the congressmen, along with Rep. Buddy Carter (R-GA) and others, took to the House floor to deliver what Drug Channels' Dr. Adam Fein referred to as a "60-minute rant" against PBMs. Read More »
Walgreens and Piedmont Healthcare recently added Piedmont Healthcare clinical services at 27 retail health clinics in Walgreens throughout Atlanta. Read More »
Leaders from the health care continuum met last month in Washington, D.C. to explore methods to enhance payment and delivery methods for the private market to create better value for patients. Read More »
The FDA has approved the New Drug Application from Teva Pharmaceutical Industries Ltd. and granted Priority Review for SD-809, a treatment for tardive dyskinesia. Read More »
Synergy Pharmacy Services recently received its Pharmacy Compounding Accreditation Board accreditation, which classifies it as a company that follows the highest quality and safety standards in the industry. Read More »
Matthew Myers, president of the Campaign for Tobacco-Free Kids, recently applauded CVS Pharmacy stores for its decision to remove tobacco products from its stores and the positive results that have already stemmed from it. Read More »
According to a recent PRNewswire release, CVS Pharmacy is the first national retail pharmacy chain to remove trans fat from their store brand food products. Read More »
The Pharmaceutical Research and Manufacturers of American (PhRMA) recently sponsored "Through the Microscope: Examining Modern Medicine," its first national health care dialogue series. Read More »
The U.S. Food and Drug Administration recently reclassified Class I devices, which are antigen-based rapid influenza antigen detection systems that are meant to detect the virus from clinical specimens, to Class II devices that are subject to special controls, according to PRNewswire. Read More »
The U.S. Food and Drug Administration has granted Perrigo Co. final approval for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup) 5 mg/1.5mg per 5 mL. Read More »
3M Drug Delivery Systems will continue its collaboration with Panacea Pharmaceuticals Inc., this time working on a new phase in its study of an investigational therapeutic cancer vaccine that would be delivered to the dermis via 3M's Hollow Microstructured Transdermal System. Read More »
CVS Health Research Institute recently released a statement on its decision to stop selling tobacco products and the research behind that decision. Read More »
Biogen Inc., a global pharmaceutical manufacture, has launched a subsidiary global hemophilia business, Bioverativ. Read More »
Palatin Technologies Inc. has closed its license agreement with AMAG Pharmaceuticals Inc. for the development of Rekynda in North America. Read More »
SPX-101, a new compound designed by Spyryx Biosciences, recently passed a Phase 1 study for the treatment of severe lung disease, including cystic fibrosis. Read More »
Portola Pharmaceuticals recently signed a $150 million royalty agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanat Alfa, an antidote for Factor Xa inhibitors. Read More »
Alerts Sign-up
